Discovering significant breakthroughs in fibrosis.
Insights from preclinical experiments and an intensive structure-based chemistry effort lead to the discovery of a library of covalent, reversible, small molecule dimeric calpain inhibitors. Currently, 2 molecules from this library are advancing into development. Additionally, our discovery work convinced us that Autotaxin, an enzyme largely responsible for extracellular lysophosphatidic acid production, is implicated in the development of hepatic and pulmonary fibrosis. We concluded an agreement to acquire a potent, clinic ready Autotaxin inhibitor, in September 2019. That molecule, now BLD-0409, will advance to the clinic in early 2020.